Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/12732
Full metadata record
DC FieldValueLanguage
dc.contributor.authorThianboonsong T.
dc.contributor.authorKanokrungsee S.
dc.contributor.authorPaichitrojjana A.
dc.contributor.authorUdompataikul M.
dc.contributor.authorKamanamool N.
dc.contributor.authorRojhirunsakool S.
dc.date.accessioned2021-04-05T03:05:24Z-
dc.date.available2021-04-05T03:05:24Z-
dc.date.issued2020
dc.identifier.issn13960296
dc.identifier.other2-s2.0-85092284609
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/12732-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85092284609&doi=10.1111%2fdth.14354&partnerID=40&md5=a28dcd44bf2325cb63658e0cc502d497
dc.description.abstractThis study evaluated the efficacy and tolerability of topical aluminum sesquichlorohydrate (AS) when compared to aluminum chloride (AC) as a treatment for primary axillary hyperhidrosis (PAH). Twenty subjects were included in this randomized, controlled, split-side 8-week study. All participants applied 20% AS and 20% AC lotions in their axillae (one treatment per axilla) every night for 2 weeks; next, the application was reduced to three times a week for 4 weeks. The assessment was performed using the sweating intensity visual scale (SIVS), hyperhidrosis disease severity score (HDSS), patient satisfaction score, and the appearance of adverse effects on weeks 0, 1, 2, 4, 6, and 8. Both AS as well as AC application showed positive results, significantly differing from the baseline, as assessed using SIVS, HDSS, and patient satisfaction score at every follow-up visit; however, no significant difference was observed between the AS and AC groups at any follow-up visit. The mean time of response was 1.14 weeks for both treatments. A side effect was observed in one subject (5%), who reported itching on the AC axilla. The therapeutic effects persisted even after reducing the frequency of application and lasted for at least 2 weeks after cessation of use. In conclusion, topical 20% AS demonstrated similar efficacy to topical 20% AC in the treatment of PAH, with a high safety profile. © 2020 Wiley Periodicals LLC.
dc.rightsSrinakharinwirot University
dc.subjectaluminum chloride
dc.subjectaluminum salt
dc.subjectaluminum sesquichlorohydrate
dc.subjectantiperspirant agent
dc.subjectnon prescription drug
dc.subjectunclassified drug
dc.subjectadult
dc.subjectArticle
dc.subjectaxilla
dc.subjectclinical article
dc.subjectclinical evaluation
dc.subjectclinical observation
dc.subjectcomparative effectiveness
dc.subjectcontrolled study
dc.subjectdisease severity assessment
dc.subjectdouble blind procedure
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectdrug tolerability
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjecthyperhidrosis
dc.subjecthyperhidrosis disease severity score
dc.subjectlotion
dc.subjectlow level laser therapy
dc.subjectmale
dc.subjectnight
dc.subjectpatient satisfaction
dc.subjectprospective study
dc.subjectpruritus
dc.subjectrandomized controlled trial
dc.subjectskin disease assessment
dc.subjectsweating intensity visual scale
dc.subjecttherapy effect
dc.subjecttopical treatment
dc.subjecttreatment response
dc.titleEfficacy and tolerability of 20% aluminum sesquichlorohydrate vs 20% aluminum chloride for the treatment of axillary hyperhidrosis: A randomized controlled trial
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationDermatologic Therapy. Vol 33, No.6 (2020)
dc.identifier.doi10.1111/dth.14354
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.